Welcome to our dedicated news page for Inari Medical (Ticker: NARI), a resource for investors and traders seeking the latest updates and insights on Inari Medical .
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Inari Medical 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Inari Medical 's position in the market.
News
Rhea-AI Summary
Inari Medical, Inc. (NARI) announced the first patient enrollment in the PEERLESS II study, a global clinical trial comparing the outcomes of intermediate-risk acute pulmonary embolism patients treated with the FlowTriever® System against traditional anticoagulation therapy. The study aims to generate evidence to influence PE treatment guidelines worldwide and establish FlowTriever as the optimal therapy for intermediate-risk PE patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
-
Rhea-AI Summary
Inari Medical, Inc. (NASDAQ: NARI) announced the completion of its acquisition of LimFlow S.A., a pioneer in limb salvage for patients with chronic limb-threatening ischemia (CLTI). The acquisition, valued at $250 million in upfront cash, with potential additional payments of up to $165 million, aligns with Inari's mission to treat patients suffering from venous and other diseases. The integration of LimFlow's technology is expected to address a significant unmet need in vascular medicine and enhance Inari's growth portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.36%
Tags
-
Rhea-AI Summary
Inari Medical, Inc. (NASDAQ: NARI) announced that its management team will be presenting at two investor conferences. The first presentation will be at the Jefferies London Healthcare Conference on November 15 in London, England. The second presentation will be at the 35th Annual Piper Sandler Healthcare Conference on November 29 in New York, NY. The presentations will be available for live audio webcasts and replays on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.28%
Tags
Rhea-AI Summary
LimFlow, a pioneer in minimally-invasive technology for treating chronic limb-threatening ischemia (CLTI), will be acquired by Inari Medical for a total potential transaction value of up to $415 million. LimFlow will receive $250 million in cash at closing and up to $165 million in additional payments based on milestones. The acquisition is expected to increase patient access to LimFlow's technology for CLTI patients. The LimFlow System is the first and only FDA-approved device for Transcatheter Arterialization of the Deep Veins (TADV).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.97%
Tags
-
Rhea-AI Summary
Inari Medical reported financial results for Q3 2023, with revenue of $126.4 million, up 31.4% YoY. They also achieved net income of $3.2 million compared to a net loss of $10.2 million in the same quarter last year. The company ended the quarter with cash and investments of $351.3 million. Inari also announced the acquisition of LimFlow, a pioneer in limb salvage for patients with chronic limb-threatening ischemia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.97%
Tags
-
Rhea-AI Summary
Inari Medical, Inc. has announced its Q3 2023 financial results and its agreement to acquire LimFlow, S.A. for $250 million in cash. LimFlow is a pioneer in limb salvage for patients with chronic limb-threatening ischemia. The acquisition is expected to close in Q4 2023. LimFlow recently received FDA approval for its Transcatheter Arterialization of Deep Veins system. The CLTI market is large and underpenetrated, impacting over 1.5 million patients globally. Inari sees this acquisition as aligned with its mission and expects it to bring clinically differentiated solutions and enhance growth opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.97%
Tags
Rhea-AI Summary
Inari Medical, Inc. to release Q3 2023 financial results on November 1, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.23%
Tags
-
Rhea-AI Summary
Inari Medical, Inc. announces participation in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.27%
Tags
-
Rhea-AI Summary
Inari Medical reports Q2 2023 financial results, with revenue of $119.0 million, up 28.3% YoY. Net income of $2.1 million, compared to a net loss of $10.2 million in Q2 2022. Launches two new products. Raises full-year revenue guidance to $482 million to $492 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.64%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.01%
Tags
Inari Medical, Inc.
Nasdaq:NARI
NARI Rankings
NARI Stock Data
2.41B
52.39M
9.55%
94.14%
6.89%
Surgical and Medical Instrument Manufacturing
Manufacturing
United States of America
IRVINE
About NARI
inari medical is a medical device company pioneering devices for the interventional treatment of vascular thrombi and emboli.